Q-omics provides the consensus-scored MYH3 profile across patient tissues and cancer cell-line models. MYH3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYH3 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, MYH3 protein abundance shows 19,193 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, KICH, and HNSC as cancer lineages where MYH3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYH3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYH3 survival associations across molecular data types. MYH3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYH3 RNA expression–survival associations across cancer types. High MYH3 expression shows unfavorable associations in KIRC, KICH, READ and ACC, but favorable associations in PAAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYH3 RNA expression.
This table summarizes MYH3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MYH3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYH3 shows lower tumor expression in KICH, THCA, BLCA, UCEC, BRCA and COAD. The KICH box plot shows higher MYH3 RNA expression in normal versus tumor tissue (log2 FC = −0.789, t-test p < 0.001).
This table shows molecular features associated with MYH3 in patient tissues and cancer cell lines. In patient samples, MYH3 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYH3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
